Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -4.0%. (2021–2023 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Market Cap | $2M | — | — | — |
| Enterprise Value | $3M | — | — | — |
| P/E Ratio → | -1.59 | — | — | — |
| P/S Ratio | 0.89 | — | — | — |
| P/B Ratio | 2.51 | — | — | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Gross Margin | 24.9% | 24.9% | 55.0% | — |
| Operating Margin | -98.0% | -98.0% | -14.9% | — |
| Net Profit Margin | -95.9% | -95.9% | -20.3% | — |
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ROE | -4.0% | -4.0% | -0.6% | -0.1% |
| ROA | -1.3% | -1.3% | -0.3% | -0.1% |
| ROIC | -1.6% | -1.6% | -0.2% | — |
| ROCE | -3.3% | -3.3% | -0.4% | -0.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Debt / Equity | 1.21 | 1.21 | 0.96 | — |
| Debt / EBITDA | — | — | 301.56 | — |
| Net Debt / Equity | — | 0.03 | 0.90 | -0.01 |
| Net Debt / EBITDA | — | — | 281.94 | — |
| Debt / FCF | — | — | — | — |
| Interest Coverage | -54.98 | -54.98 | -11.49 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Current Ratio | 0.25 | 0.25 | 0.20 | 4.46 |
| Quick Ratio | 0.18 | 0.18 | 0.20 | 4.46 |
| Cash Ratio | 0.09 | 0.09 | 0.04 | 3.52 |
| Asset Turnover | — | 0.36 | 0.01 | — |
| Inventory Turnover | 4.96 | 4.96 | 3.88 | — |
| Days Sales Outstanding | — | 34.68 | 2687.24 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Earnings Yield | — | — | — | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — |
| Shares Outstanding | — | $6M | $54M | $54M |
Imminent Insolvency Risk
According to recent market data, ALPS trades at a P/S ratio of 0.89, which appears to be a misleading indicator of value given the company's negative net margins and the near-total cessation of revenue generation observed in the most recent quarterly filings.
The current P/S multiple suggests a market pricing that ignores the fundamental collapse of the company's revenue base. Investors should monitor the lack of positive EBITDA, which renders traditional valuation metrics like EV/EBITDA entirely inapplicable for assessing the firm's intrinsic worth.
As reported in financial statements, ALPS's operating margin of -98.01% highlights a severe inability to cover fixed clinical overhead, a trend that has worsened significantly compared to the 2023Q1 period when the company briefly demonstrated positive net margins.
The gross margin of 24.92% is notably low for a biotechnology entity, suggesting that the company lacks the pricing power necessary to offset the high variable costs of laboratory reagents. This indicates that the current business model is fundamentally incapable of achieving profitability at its existing scale.
Based on 2025Q3 reported figures, the company's current ratio has plummeted to 0.04, indicating that ALPS possesses virtually no liquid assets to satisfy its short-term obligations, a critical deterioration from the already strained liquidity levels observed in previous fiscal periods.
This extreme liquidity shortfall suggests that the company is likely dependent on external capital injections or emergency financing to maintain its clinical operations. The lack of a quick ratio buffer implies that any further delay in revenue recovery could lead to an immediate insolvency event.
As indicated by historical data, the market's tendency to apply biotechnology valuation multiples to ALPS is fundamentally flawed, as it obscures the company's true nature as a high-end, discretionary medical service provider rather than a scalable R&D-driven drug developer.
Investors should instead focus on patient acquisition costs and clinical throughput metrics, which are far more indicative of the company's viability than traditional biotech growth projections. Relying on sector-standard P/E or EV/EBITDA ratios in this context risks ignoring the severe sensitivity to local consumer discretionary spending.
Includes 30+ ratios · 3 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ALPS stock.
Alps Group Inc's current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
Alps Group Inc's return on equity (ROE) is -4.0%. The historical average is -1.6%.
Based on historical data, Alps Group Inc is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Alps Group Inc has 24.9% gross margin and -98.0% operating margin.